[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proliferative-diabetic-retinopathy-pdr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proliferative-diabetic-retinopathy-pdr":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100576860","phase-3-faricimab--prp-vs-vitrectomy--endolaser-for-treatment-of-pdr-100576860",false,"NCT06790784","Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR","A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy","AP","Inclusion Criteria:\n\nIndividual:\n\n* ≥ 18 years old\n* Diagnosis of diabetes mellitus (type 1 or type 2)\n\nStudy Eye:(A participant can have one or two study eyes if both eyes are eligible at screening.)\n\n* Presence of PDR requiring treatment, defined as moderate PDR or worse on global grading of ultrawide field fundus photos or NV meeting criteria for moderate PDR or worse on global grading of ultrawide field FA, confirmed by a central reading center\n* Best corrected visual acuity ≥49 letters (20\u002F100 Snellen equivalent or better)\n\nExclusion Criteria:\n\n* Individual:\n\n  * Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.\n  * Blood pressure \\> 160\u002F100 (systolic above 160 or diastolic above 100).\n\n    o If blood pressure is brought below 160\u002F100 by anti-hypertensive treatment, individual can become eligible.\n  * For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years.\n\n    * Women of childbearing potential will be required to have pregnancy testing or use an acceptable method of pregnancy prevention. Women who are potential study participants should be questioned about the potential for pregnancy at baseline and prior to each injection. Pregnancy test is required for all women of childbearing potential at baseline. Investigator judgment is used to determine when a pregnancy test is needed during follow up.\n\nStudy Eye: (A participant can have two study eyes.)\n\n* Traction retinal detachment involving the macula\n* Significant vitreous hemorrhage that would preclude completion of a full PRP\n* Significant vitreomacular traction\n* Any prior vitrectomy\n* Any prior PRP (defined as ≥100 burns outside of the posterior pole)\n* Treatment for DME within the prior 6 months\n* Intravitreal anti-VEGF for any indication, other than DME, within the prior year","ALL","18 Years",{"count":20,"type":21},426,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.",[27],"Proliferative Diabetic Retinopathy (PDR)",[29,30,31,32],"faricimab","vitrectomy","endolaser","panretinal photocoagulation","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2025-08-04",{"date":41,"type":21},"2031-08",{"name":43,"class":44},"Jaeb Center for Health Research","OTHER",28,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100640460","early-vitrectomy-vs-prp-in-early-proliferative-diabetic-retinopathy-100640460","NCT07586787","Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy","Comparison of Early Micro-invasive Vitrectomy Surgery Versus Panretinal Photocoagulation for the Treatment of Early Proliferative Diabetic Retinopathy: A Multi-center Randomized Trial","Inclusion Criteria:\n\n* Age 18 years or older.\n\nDiagnosis of type 2 diabetes mellitus.\n\nPresence of early proliferative diabetic retinopathy with active neovascularization, or mild vitreous hemorrhage or preretinal hemorrhage that does not interfere with evaluation of neovascularization.\n\nRelatively clear optical media, good pupillary dilation, and sufficient cooperation for panretinal photocoagulation and retinal imaging.\n\nAbility and willingness to provide written informed consent.\n\nIf both eyes are eligible, the eye with worse vision will be included.\n\nExclusion Criteria:\n\n* Prior panretinal photocoagulation, macular photocoagulation, or vitrectomy in the study eye.\n\nRetinal traction or retinal detachment.\n\nOptic neuropathy.\n\nMacular edema caused by reasons other than diabetes.\n\nCoexisting ocular disease that may decrease visual acuity during the study.\n\nSubstantial cataract likely to decrease visual acuity by more than three lines.\n\nMajor ocular surgery within the past 4 months or planned intraocular surgery within the next 6 months.\n\nYAG capsulotomy within the past 2 months.\n\nAny intravitreal injection within the past 3 months.\n\nAphakia.\n\nSevere external ocular infection.\n\nUncontrolled glaucoma.\n\nSignificant renal disease requiring dialysis or kidney transplantation.\n\nUnstable glycemic control.\n\nBlood pressure greater than 180\u002F110 mmHg.\n\nHistory of transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiac event requiring hospitalization within the past 4 months.\n\nPregnant, lactating, or intending to become pregnant during the study period.\n\nParticipation in another clinical trial.\n\nUnwilling or unable to provide informed consent, undergo randomization, or return for scheduled visits.",{"count":54,"type":21},100,[56],"NA","The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). It will also evaluate the safety and functional outcomes of early surgical intervention in this population.\n\nThe main questions it aims to answer are:\n\nDoes early MIVS increase the proportion of eyes achieving complete regression of retinal neovascularization at 12 months? Does early MIVS improve visual and functional outcomes, including visual acuity and visual field, compared to PRP? Researchers will compare early MIVS combined with peripheral scatter photocoagulation to standard PRP to determine whether early surgical intervention leads to better regression of neovascularization and improved clinical outcomes.\n\nParticipants will:\n\nReceive either MIVS with peripheral photocoagulation or standard PRP Undergo retinal imaging assessments including fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA) Complete follow-up visits over 12 months, including visual acuity testing, visual field testing, and optical coherence tomography (OCT) imaging Be monitored for the occurrence of vitreous hemorrhage and other clinical outcomes",[27],[60,61,62,63],"Panretinal photocoagulation","Proliferative diabetic retinopathy","Retinal neovascularization","Vitrectomy","2026-05-07",{"date":66,"type":37},"2026-05-14",{"date":68,"type":37},"2025-01-01",{"date":70,"type":21},"2026-06-10",{"name":72,"class":44},"Xiamen Ophthalmology Center Affiliated to Xiamen University",6]